Clinical Trial

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn: * About the safety of MK-1084 and if people tolerate it when taken with other treatments * How many people have the cancer respond (get smaller or go away) to the treatments
Protocol Amendment History 7 changes
notable Enrollment reduced: 190 -> 140 participants 2026-07-23
notable Primary completion moved earlier: 2031-08-11 -> 2029-08-17 2026-07-23
notable Trial sites expanded: 21 -> 24 locations 2026-06-19
notable Trial sites expanded: 18 -> 21 locations 2026-06-13
minor Completion moved earlier: 2037-05-06 -> 2032-04-13 2026-06-13
notable Trial sites expanded: 12 -> 18 locations 2026-05-27
notable Trial sites expanded: 4 -> 12 locations 2026-05-15
Trial Details
NCT Number NCT07286149
Lead Sponsor Merck Sharp & Dohme LLC
Collaborators: Daiichi Sankyo
Conditions Lung Neoplasm Malignant
Enrollment 140 participants
Start Date 2026-04-30
Primary Completion 2029-08-17 (estimated)
Study Completion 2032-04-13 (estimated)
Updated on ClinicalTrials.gov 2026-08-06